Russo Giuseppe, Laffitte Emmanuel
Service de dermatologie et vénéréologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
Rev Med Suisse. 2023 Mar 29;19(820):606-613. doi: 10.53738/REVMED.2023.19.820.606.
Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL-4 receptor inhibiting the signaling of interleukin-4 and interleukin-13, two major cytokines in type 2 inflammatory diseases such as atopic dermatitis, asthma and nasosinusal polyposis. Since its approval for atopic dermatitis in 2017, the molecule has occasionally been used off-label in several dermatological conditions where standard treatments are often disappointing.Furthermore, what emerges from the data currently in the literature is a favourable safety profile with few, reversible side effects.
